Galapagos (GLPG.AS) Stock Price
Galapagos Price
Revenue has compounded at 19.9% per year over the past 19 years to 1.11 B EUR. Earnings per share have grown at 25.0% per year over the last 16 years. Galapagos's net margin stands at 28.9%, up from -25.9% several years earlier. Analysts set a median price target of 28.46 EUR, implying 8.5% above the current price. Of 18 analysts, 3 rate the stock a buy — an overall Sell consensus.
Galapagos stock price
Galapagos business model & stock analysis
Frequently asked questions about Galapagos
The business model of Galapagos NV is centered around the discovery, development, and commercialization of innovative medicines. The company primarily focuses on the development of small molecule drugs that target specific proteins involved in various diseases. With a strong emphasis on research and development, Galapagos NV collaborates with partners in the pharmaceutical industry to bring novel therapies to patients. By leveraging its proprietary target discovery platform, the company identifies potential drug targets and advances them through preclinical and clinical development stages. Through strategic collaborations and licensing agreements, Galapagos NV aims to bring its pipeline of promising drug candidates to market, addressing unmet medical needs and contributing to improved patient outcomes.
Galapagos NV is primarily active in the biotechnology and pharmaceutical industries.
Galapagos NV faces competition from various pharmaceutical companies in the market. Some of the main competitors include companies like Novartis, Johnson & Johnson, Pfizer, and Roche. These companies operate in similar therapeutic areas and compete with Galapagos NV in developing innovative drug candidates and therapies. Galapagos NV strives to maintain a competitive edge by leveraging its distinctive scientific expertise, robust pipeline, and strategic collaborations.
Galapagos NV is a renowned biotechnology company headquartered in Mechelen, Belgium. Founded in 1999, Galapagos NV has established itself as a leader in drug discovery and development. The company focuses on the discovery and development of small molecule medicines with a specialization in inflammation, fibrosis, and other diseases. Galapagos NV has an excellent track record of successful collaborations with pharmaceutical giants such as Gilead Sciences. With a strong commitment to innovation and advancement, Galapagos NV continues to make significant contributions to the healthcare industry, bringing hope and potential for novel treatments to patients worldwide.
Galapagos NV, a renowned biotechnology company, has accomplished several notable milestones over the years. The company has made significant progress in developing innovative therapies for various diseases. It successfully advanced its lead drug candidate, Filgotinib, through multiple clinical trials, demonstrating promising results in treating rheumatoid arthritis, Crohn's disease, and other inflammatory conditions. Galapagos NV has also fostered strong partnerships with major pharmaceutical companies to further advance its research pipeline. Furthermore, the company received regulatory approvals for its products in various regions, solidifying its position as a pioneer in the biotech industry. Galapagos NV continues to drive innovation, striving to improve patients' lives through groundbreaking discoveries.
Galapagos NV primarily operates in several countries and regions. The company has a significant presence in Europe, specifically in Belgium and the Netherlands, where its headquarters are located. Galapagos also has operations and offices in France, Spain, Italy, Switzerland, and the United Kingdom. Furthermore, the company has expanded its footprint across the Atlantic, with a presence in the United States and Canada. With its global presence, Galapagos NV is able to leverage diverse markets and collaborations to further its research, development, and commercialization efforts.
Galapagos NV represents a commitment to innovation, collaboration, and scientific excellence. The company values diversity and fosters an entrepreneurial spirit within its teams. Galapagos NV's corporate philosophy revolves around a patient-centric approach, aiming to develop transformative medicines that improve the lives of patients. By leveraging cutting-edge technology and extensive research, the company strives to bring forth breakthrough therapies for various diseases. Galapagos NV's dedication to research and development, along with its emphasis on partnerships and scientific expertise, drives its mission to deliver innovative solutions to healthcare challenges.
Analysts currently set an average price target of 30.17 EUR for the Galapagos stock (median: 28.46 EUR), implying +15.1 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Galapagos stock: 3 recommend buying, 6 holding and 9 selling. For 2026, analysts expect Galapagos to generate revenue of 271.90 M EUR and earnings per share of -3.05 EUR.
The Galapagos share (GLPG.AS) is listed on 10 stock exchanges, including: London (0JXZ.L), XETRA (GXE.DE), Frankfurt (GXE.F), München (GXE.MU), Düsseldorf (GXE.DU), Wien (GLPG.VI), Amsterdam (GLPG.AS).
Galapagos NV is a biotechnology company specialized in the discovery and development of new drugs for a variety of diseases. Its business model is based on a three-step strategy: Target Discovery, Drug Development, and Clinical Candidate Development. The company uses proprietary technologies, including AI methods and big data analysis, to identify promising target molecules and develop potential drugs. These drugs are then tested for efficacy and safety in clinical studies, with the goal of bringing new treatments to market faster and more efficiently. Galapagos also collaborates with other companies and organizations to develop innovative treatment options, such as their partnership with Gilead Sciences for the development of drugs for Idiopathic Pulmonary Fibrosis. Overall, Galapagos strives to advance the discovery and development of drugs for various diseases through the use of innovative technologies and collaboration with experts in the field.
The expected revenue of Galapagos is 271.90 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Galapagos is -200.96 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Galapagos is currently -8.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Galapagos stock.
The price-to-sales ratio (P/S) of Galapagos is currently 6.35. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Galapagos stock.
The Eulerpool Quality Score for Galapagos is 5/10.
The ISIN of Galapagos is BE0003818359. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Galapagos is A0EAT9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Galapagos is GLPG.AS. The ticker symbol is used to trade Galapagos shares on the stock exchange.
Galapagos stock
All fundamentals and in-depth analysis of Galapagos
Our stock analysis for Galapagos stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Galapagos. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.